array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2444) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(63) "US Intensifies Drug Discount Debate in Latest Regeneron Lawsuit" ["snippet_en"]=> string(218) "New Justice Department allegations that Regeneron Pharmaceuticals Inc. artificially inflated Medicare reimbursement rates on a high-earning eye treatment are likely to trigger copycat complaints at other manufacturers." ["url"]=> string(105) "https://news.bloomberglaw.com/us-law-week/us-intensifies-drug-discount-debate-in-latest-regeneron-lawsuit" ["image_url"]=> string(78) "https://images.businessradar.com/articles/435ec56d-4f91-4384-b5ae-96baa87ad0ff" ["source"]=> string(16) "bloomberglaw.com" ["publication_date"]=> string(10) "2024-04-12" ["categories"]=> array(4) { [0]=> string(5) "Legal" [1]=> string(12) "Slash Prices" [2]=> string(31) "Financial Update/Profit Warning" [3]=> string(11) "US Politics" } } [1]=> array(7) { ["title_en"]=> string(62) "REGN - Regeneron to Report First Quarter 2024 Financial and..." ["snippet_en"]=> string(142) "TARRYTOWN N.Y. April 01 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ) today announced that it will report its first." ["url"]=> string(115) "https://marketwirenews.com/news-releases/regeneron-to-report-first-quarter-2024-financial-and-6813907667533457.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/57ebf7e6-5756-4c2e-b966-e6d933818ef7" ["source"]=> string(18) "marketwirenews.com" ["publication_date"]=> string(10) "2024-04-01" ["categories"]=> array(2) { [0]=> string(31) "Financial Update/Profit Warning" [1]=> string(24) "Quarterly/Annual Figures" } } [2]=> array(7) { ["title_en"]=> string(87) "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Ritholtz Wealth Management" ["snippet_en"]=> string(256) "Ritholtz Wealth Management decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission." ["url"]=> string(127) "https://www.defenseworld.net/2024/04/01/regeneron-pharmaceuticals-inc-nasdaqregn-shares-sold-by-ritholtz-wealth-management.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/b395be10-d1fb-4a93-a488-056eaf2d86bb" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2024-04-01" ["categories"]=> array(5) { [0]=> string(18) "General Investment" [1]=> string(11) "Regulations" [2]=> string(24) "Stock Research & Ratings" [3]=> string(31) "Financial Update/Profit Warning" [4]=> string(12) "Stock Market" } } [3]=> array(7) { ["title_en"]=> string(157) "Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024 - TipRanks.com" ["snippet_en"]=> string(169) "TARRYTOWN, N.Y., Jan. 05, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full y..." ["url"]=> string(186) "https://www.tipranks.com/news/press-releases/regeneron-to-report-fourth-quarter-and-full-year-2023-financial-and-operating-results-and-host-conference-call-and-webcast-on-february-2-2024" ["image_url"]=> NULL ["source"]=> string(12) "tipranks.com" ["publication_date"]=> string(10) "2024-01-05" ["categories"]=> array(3) { [0]=> string(5) "Event" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(24) "Quarterly/Annual Figures" } } [4]=> array(7) { ["title_en"]=> string(85) "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Pinnacle Associates Ltd." ["snippet_en"]=> string(300) "Pinnacle Associates Ltd. lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,483 shares of the biopharm" ["url"]=> string(76) "https://www.marketbeat.com/instant-alerts/nasdaq-regn-sec-filing-2024-01-01/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/14936b9d-dcc9-4a3c-ba8a-c2ceefa40086" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2024-01-01" ["categories"]=> array(5) { [0]=> string(18) "General Investment" [1]=> string(11) "Regulations" [2]=> string(31) "Financial Update/Profit Warning" [3]=> string(20) "Corporate Governance" [4]=> string(12) "Stock Market" } } [5]=> array(7) { ["title_en"]=> string(100) "Global Retirement Partners LLC Purchases 100 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(223) "Global Retirement Partners LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 67.1% during the 3rd quarter, according to the company in its most recent filing with the SEC." ["url"]=> string(140) "https://www.defenseworld.net/2023/12/27/global-retirement-partners-llc-purchases-100-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/ea88b4c0-36a5-4473-b0a3-9af0e5140973" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-12-27" ["categories"]=> array(11) { [0]=> string(18) "General Investment" [1]=> string(15) "Market Movement" [2]=> string(11) "Acquisition" [3]=> string(14) "Issuing Shares" [4]=> string(11) "Regulations" [5]=> string(24) "Stock Research & Ratings" [6]=> string(24) "Quarterly/Annual Figures" [7]=> string(13) "Credit Rating" [8]=> string(31) "Financial Update/Profit Warning" [9]=> string(16) "Share Repurchase" [10]=> string(12) "Stock Market" } } [6]=> array(7) { ["title_en"]=> string(101) "Regeneron Pharmaceuticals, Inc.: Regeneron Reports Third Quarter 2023 Financial and Operating Results" ["snippet_en"]=> string(203) "Third quarter 2023 revenues increased 15% to $3.36 billion versus third quarter 2022Third quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 33% to $3.10 billion versus third quarter" ["url"]=> string(168) "https://www.finanznachrichten.de/nachrichten-2023-11/60544775-regeneron-pharmaceuticals-inc-regeneron-reports-third-quarter-2023-financial-and-operating-results-399.htm" ["image_url"]=> string(78) "https://images.businessradar.com/articles/24829205-fd91-427a-898d-a7929a077bcc" ["source"]=> string(20) "finanznachrichten.de" ["publication_date"]=> string(10) "2023-11-02" ["categories"]=> array(2) { [0]=> string(31) "Financial Update/Profit Warning" [1]=> string(24) "Quarterly/Annual Figures" } } [7]=> array(7) { ["title_en"]=> string(57) "Alnylam (ALNY) Q2 Loss Wider Than Expected, Revenues Miss" ["snippet_en"]=> string(199) "Alnylam (ALNY) reports weaker-than-expected second-quarter results. The company also provides updates on its pipeline candidates, which are being developed in collaboration with other pharma bigwigs." ["url"]=> string(67) "https://au.news.yahoo.com/alnylam-alny-q2-loss-wider-152400145.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/96d82ba7-4d8e-4486-924f-98ae09f967b9" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2023-08-04" ["categories"]=> array(4) { [0]=> string(13) "Collaboration" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(21) "Financial Performance" [3]=> string(24) "Quarterly/Annual Figures" } } [8]=> array(7) { ["title_en"]=> string(81) "Regeneron hopes for quick FDA decision on high-dose Eylea as Roche's rival surges" ["snippet_en"]=> string(271) "In a high-stakes race of their eye disease drugs, Roche has sprinted to a significant lead over Regeneron. | Playing catch-up with Roche in a war of eye disease treatments, Regeneron hopes to gain an FDA decision for its recently rejected high-dose Eylea in this quarter." ["url"]=> string(117) "https://www.fiercepharma.com/pharma/roches-vabysmo-surging-regeneron-hopes-third-quarter-fda-decision-high-dose-eylea" ["image_url"]=> string(78) "https://images.businessradar.com/articles/4e17d527-d855-456e-95a5-6c57d54b707d" ["source"]=> string(16) "fiercepharma.com" ["publication_date"]=> string(10) "2023-08-03" ["categories"]=> array(1) { [0]=> string(31) "Financial Update/Profit Warning" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(197) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(193) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(152) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(101) } [4]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(95) } [5]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(83) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(70) } [7]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(61) } [8]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(51) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(50) } [10]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(46) } [11]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(44) } [12]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(35) } [13]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(35) } [14]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(34) } [15]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [16]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(33) } [17]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(32) } [18]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(31) } [19]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(31) } [20]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(31) } [21]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(30) } [22]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(29) } [23]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(29) } [24]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(27) } [25]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(26) } [26]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(24) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(23) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(20) } [29]=> array(2) { ["name"]=> string(8) "Politics" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc